Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

BACKGROUND: Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many genetic causes, and recent studies suggest the important role of ESR1 mutations and f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Lin, Ling, Veeraraghavan, Jamunarani, Hu, Yiheng, Wang, Xian, Lee, Sanghoon, Tan, Ying, Schiff, Rachel, Wang, Xiao-Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414578/
https://www.ncbi.nlm.nih.gov/pubmed/32771039
http://dx.doi.org/10.1186/s13058-020-01325-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414578/
https://www.ncbi.nlm.nih.gov/pubmed/32771039
http://dx.doi.org/10.1186/s13058-020-01325-3

Ejemplares similares